Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTEGRIS-PSC
NL-OMON56399Phase 2Recruiting
- Sponsor
- Pliant Therapeutics
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bexotegrast in Primary Sclerosing Cholangitis (PSC), sponsored by Pliant Therapeutics. Started Sep 2022; status: recruiting.
02
Drugs
bexotegrast
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NL-OMON56399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56399.